logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Hiv1

    Medications for Hiv1

    FiltersReset Filters
    25 results

    • abacavir and lamivudine

      (Abacavir and Lamivudine)
      Laurus Labs Limited
      Usage: Abacavir and lamivudine tablets are indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection when used in combination with other antiretroviral agents.

    • apretude

      (Cabotegravir)
      ViiV Healthcare Company
      Usage: APRETUDE is indicated for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing at least 35 kg who are at risk of HIV-1. A negative HIV-1 test is required before starting treatment.

    • biktarvy

      (bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate)
      Gilead Sciences, Inc.
      Usage: BIKTARVY is indicated for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 14 kg, either as a complete regimen for those with no antiretroviral treatment history or as a replacement for those who are virologically suppressed on a stable regimen without resistance issues.

    • darunavir

      (Darunavir)
      Amneal Pharmaceuticals NY LLC
      Usage: Darunavir, when combined with ritonavir and other antiretroviral agents, is indicated for the treatment of HIV-1 infection in patients aged 3 years and older.

    • edurant

      (rilpivirine hydrochloride)
      Janssen Products, LP
      Usage: EDURANT is indicated for the treatment of HIV-1 in treatment-naïve patients aged 2 and older with specific viral loads. It is also used in combination with cabotegravir for short-term treatment in adults and adolescents who are virologically suppressed and require an oral lead-in or temporary oral therapy.

    • efavirenz

      (Efavirenz)
      Aurobindo Pharma Limited
      Usage: Efavirenz capsules, in combination with other antiretroviral agents, are indicated for treating HIV-1 infection in adults and pediatric patients aged at least 3 months and weighing a minimum of 3.5 kg.

    • efavirenz

      (Efavirenz)
      Macleods Pharmaceuticals Limited
      Usage: Efavirenz, in combination with other antiretroviral agents, is indicated for treating HIV-1 infection in adults and pediatric patients aged at least 3 months who weigh at least 3.5 kg.

    • emtricitabine

      (Emtricitabine)
      Aurobindo Pharma Limited
      Usage: Emtricitabine capsules are indicated for the treatment of HIV-1 infection, to be used in combination with other antiretroviral medications.

    • emtricitabine

      (emtricitabine)
      Cipla USA Inc.
      Usage: Emtricitabine is indicated for the treatment of HIV-1 infection, used in combination with other antiretroviral agents.

    • emtricitabine and tenofovir disoproxil fumarate

      (Emtricitabine and Tenofovir Disoproxil Fumarate)
      Amneal Pharmaceuticals NY LLC
      Usage: Emtricitabine and tenofovir disoproxil fumarate tablets are indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥17 kg) and for pre-exposure prophylaxis (PrEP) in at-risk adolescents and adults (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection.